Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic
- 1Mayo Clinic
Abstract
IntroductionRemote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition. This study evaluates the feasibility of implementing Mayo Test Drive (MTD), a remote, self-administered digital cognitive assessment, within a specialized clinic focused on eligibility assessments for anti-amyloid therapies for Alzheimers disease (AD).
MethodTwo-hundred and nine (N=209) patients (Mage=71.2, 53% female) were evaluated through the Mayo Clinic Rochester Alzheimers Disease Treatment Clinic (ADTC) and had the opportunity to complete MTD, either as a remote, patient-initiated session through a patient-facing healthcare portal or during an in-clinic neuropsychological evaluation.
ResultsClinical diagnoses included 55.2% mild cognitive impairment (MCI), 31.0% mild dementia, and 11.6% moderate dementia, in addition to 2.2% cognitively unimpaired (CU), as determined by neurology consensus at a multidisciplinary case conference. Among those who initiated MTD (n=197/209), 97.5% completed a session (70.6% remotely, 26.9% in clinic). Completion rates were high across diagnostic groups and did not significantly differ by clinical severity (p=.12): CU (100%), MCI (99.1%), mild dementia (97.0%), and moderate dementia (89.5%). Remote completion rates overall were high (97.9%). Among completers, administration setting (remote vs. in-clinic) did not significantly differ by clinical stage, {chi}{superscript 2}(3)=2.37, p=.49. Reasons for non-initiation included not receiving or opening portal messages and other/unknown factors.
DiscussionRemote digital cognitive assessment is feasible within the context of clinic eligibility evaluations for AD therapies. The high completion rates of MTD across clinical impairment levels in this setting support development of paths for broader use in cognitive characterization in AD care.
Related
- Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer's disease PET imaging biomarkers
- Home-administered unfocused transcranial ultrasound in subjective cognitive decline and dementia: an open-label, uncontrolled feasibility pilot study
- Remote self-administered speech assessment in clinical neurology: feasibility, data quality, and equity in 1,000 consecutive patients
- Language Impairment in Alzheimer's Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026.
- Practice Effects on Repeated Self-Administered Digital Cognitive Assessments in Cognitively Intact Older Adults from the Framingham Heart Study: Longitudinal Observational Study.
BibTeX
@misc{kaser2026feasibility,
title = {{Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic}},
author = {A. N. Kaser and J. L. Stricker and M. A. Hughes and N. Corriveau-Lecavalier and E. A. Boots and M. M. Machulda and J. A. Fields and D. T. Jones and S. J. McCarter and H. Botha and R. P. Coburn and C. Bermudez and B. J. Neth and J. Graff-Radford and V. K. Ramanan and N. H. Stricker},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.15.26362283},
url = {https://www.medrxiv.org/content/10.64898/2026.09.15.26362283v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic
AU - A. N. Kaser
AU - J. L. Stricker
AU - M. A. Hughes
AU - N. Corriveau-Lecavalier
AU - E. A. Boots
AU - M. M. Machulda
AU - J. A. Fields
AU - D. T. Jones
AU - S. J. McCarter
AU - H. Botha
AU - R. P. Coburn
AU - C. Bermudez
AU - B. J. Neth
AU - J. Graff-Radford
AU - V. K. Ramanan
AU - N. H. Stricker
PY - 2026
DA - 2026/09/15
PB - medRxiv
DO - 10.64898/2026.09.15.26362283
UR - https://www.medrxiv.org/content/10.64898/2026.09.15.26362283v1
AB - IntroductionRemote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition. This study evaluates the feasibility of implementing Mayo Test Drive (MTD), a remote, self-administered digital cognitive assessment, within a specialized clinic focused on eligibility assessments for anti-amyloid therapies for Alzheimers disease (AD). MethodTwo-hundred and nine (N=209) patients (Mage=71.2, 53% female) were evaluated through the Mayo Clinic Rochester Alzheimers Disease Treatment Clinic (ADTC) and had the opportunity to complete MTD, either as a remote, patient-initiated session through a patient-facing healthcare portal or during an in-clinic neuropsychological evaluation. ResultsClinical diagnoses included 55.2% mild cognitive impairment (MCI), 31.0% mild dementia, and 11.6% moderate dementia, in addition to 2.2% cognitively unimpaired (CU), as determined by neurology consensus at a multidisciplinary case conference. Among those who initiated MTD (n=197/209), 97.5% completed a session (70.6% remotely, 26.9% in clinic). Completion rates were high across diagnostic groups and did not significantly differ by clinical severity (p=.12): CU (100%), MCI (99.1%), mild dementia (97.0%), and moderate dementia (89.5%). Remote completion rates overall were high (97.9%). Among completers, administration setting (remote vs. in-clinic) did not significantly differ by clinical stage, {chi}{superscript 2}(3)=2.37, p=.49. Reasons for non-initiation included not receiving or opening portal messages and other/unknown factors. DiscussionRemote digital cognitive assessment is feasible within the context of clinic eligibility evaluations for AD therapies. The high completion rates of MTD across clinical impairment levels in this setting support development of paths for broader use in cognitive characterization in AD care.
ER -